Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of BMS-986263 in compensated cirrhosis due to NASH
2019-003932-22Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis and Cirrhosis comparing BMS-986263 with Placebo (2 arms). Started Jun 2020; status: completed.
02
Drugs
ND-L02-s0201
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)hepatic fibrosisCirrhosis
Beyond the preview
Go deeper on 2019-003932-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003932-22.